Xconomy National Biotech Editor Alex Lash welcomes the attendees of What's Hot in Seattle Biotech 2018.
Photo by I Sometimes Dream | Event Photography
Leen Kawas, right, CEO of M3 Biotechnology, speaks during the neuroscience panel while Amy Bernard of the Allen Institute for Brain Science looks on.
Photo by I Sometimes Dream | Event Photography
Heather Franklin, CEO of Blaze Bioscience, discusses "tumor paint" during one of three cancer startup spotlights.
Photo by I Sometimes Dream | Event Photography
Jon Congleton (right), CEO of Impel NeuroPharma, addresses the neuroscience panel.
Photo by I Sometimes Dream | Event Photography
VK Gadi, co-founder and medical director of SEngine Precision Medicine, speaks in one of the cancer startup spotlight talks.
Photo by I Sometimes Dream | Event Photography
Attendees make connections during the networking break.
Photo by I Sometimes Dream | Event Photography
What's Hot in Seattle Biotech attendees share their thoughts during the networking break.
Photo by I Sometimes Dream | Event Photography
Harlan Robins (center), head of innovation and co-founder of Adaptive Biotechnologies, explains his company's partnership with Microsoft.
Photo by I Sometimes Dream | Event Photography
Bill Watt, CEO of EpiThany, speaks during one of the cancer startup spotlight talks.
Photo by I Sometimes Dream | Event Photography
Dan Wattendorf, director of innovative technology solutions at the Bill & Melinda Gates Foundation, speaks about biotech innovations.
Photo by I Sometimes Dream | Event Photography
Universal Cells CEO Claudia Mitchell (center) speaks during the startups panel.
Photo by I Sometimes Dream | Event Photography
What's Hot in Seattle Biotech attendees making connections during the networking reception.
Photo by I Sometimes Dream | Event Photography
Lara Mangravite (center), president of Sage Bionetworks, speaks during the big data panel.
Photo by I Sometimes Dream | Event Photography
Amy Bernard (left), a neuroscience panelist, makes a connection during the networking break.
Photo by I Sometimes Dream | Event Photography
Like a good cup of coffee, Seattle’s life sciences ecosystem is a balanced blend of complementary parts: research to find the underpinnings of disease, and information technology that helps scientists make sense of the data. That convergence was on display last week at Xconomy’s annual What’s Hot in Seattle Biotech event. Here are a few highlights from the day:
Researchers in Seattle are already availing themselves of powerful new tools in their quest to understand disease and find new treatments. The Allen Institute for Brain Science is creating databases and crunching data that could pave the way for new neuroscience discoveries. Others are also taking a big data approach to disease. Both Leen Kawas, CEO of M3 Biotechnology, and Harlan Robins, head of innovation at Adaptive Biotechnolgies, pointed out how the search for new healthcare solutions is advancing with big data analysis. M3’s lead drug is an experimental regenerative treatment for Alzheimer’s disease. Adaptive and Microsoft are joining forces to develop new diagnostics. Autoimmune disease is their first target.
Patients may not realize it, but big data analytics is already playing a role in how they receive their care. Nicholas Mark, medical director at KenSci, explained how his startup’s technology analyzes the flow of patients in a hospital. The software can then predict times when the hospital will be busiest, helping administrators manage staffing schedules.
Cancer research continues to hold a prominent place in the Seattle life sciences community, and we showcased three startups that are contributing to it. Blaze Bioscience is testing a new way of spotting cancer, EpiThany is developing a cancer vaccine, and SEngine Precision Medicine has brought to the market a new way to match patients to cancer treatments.
Building a life science company in Seattle does have challenges. The region doesn’t benefit from the presence of a large pharmaceutical company, nor does it draw venture capital investment at the levels of larger markets, such as Boston and the Bay Area. But Phase Genomics CEO Ivan Liachko pointed out that venture capital isn’t the only way to grow a business, as his mostly bootstrapped startup was able to commercialize a technology that helps researchers obtain genomic data from microbiome samples. Claudia Mitchell, CEO of Universal Cells, noted that partnerships with larger companies offer a path for smaller startups to finance and develop their technologies.
We’d like to thank Cambia Grove, which hosted What’s Hot in Seattle Biotech. We also want to extend our thanks to sponsors BioCrossroads, ICON, and ARCH Venture Partners, whose support made the event possible. Photos of the speakers and the event are courtesy of I Sometimes Dream | Event Photography. And last, but not least, thank you to all of the attendees who came to hear more about the new ideas and technologies that are brewing in the Seattle-area life sciences scene.
Photo by Flickr user Tiffany Von Arnim, cropped to fit Xconomy’s publishing system standards and used under a Creative Commons license
Frank Vinluan is an Xconomy editor based in Research Triangle Park. You can reach him at [email protected] Follow @frankvinluan
Join us on July 16 for a special two-part gathering that will take a unique and critical look at the Internet today, and where it is heading.
Sponsored · Webinar
Phenotypic Screening & Profiling to Understand a Compound's Disease Impact
Eurofins DiscoverySponsored · Webinar
How Functional Cell-based Assays Support Clinical Programs Managing Proinflammatory Cytokines Associated with High Mortality
Eurofins DiscoverXSponsored · Webinar
Provide an in vitro drug-induced proarrhythmia assessment & strengthen pharmacological safety profiles of drug candidates
Eurofins DiscoverX© 2007-2022, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.